Old Web
English
Sign In
Acemap
>
authorDetail
>
Nabanita Mukherjee
Nabanita Mukherjee
Novartis
Oncology
Internal medicine
Medicine
PI3K/AKT/mTOR pathway
Dose Reduced
2
Papers
24
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase II studies of BEZ235 in patients with advanced pancreatic neuroendocrine tumors (pNET).
2015
Journal of Clinical Oncology
Ramon Salazar
Chris Verslype
Eric Baudin
Steven K. Libutti
James C. Yao
Roberto Buzzoni
Lorenzo Antonuzzo
Richard Hubner
Rocio Garcia-Carbonero
Ana Custodio
Edward M. Wolin
Sabine Turri
Debarshi Dey
Paola Aimone
Joseph Sulovski
Nabanita Mukherjee
Fabian Herbst
Nicola Fazio
Show All
Source
Cite
Save
Citations (8)
An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL)
2014
Blood
Anas Younes
Gilles Salles
Giovanni Martinelli
R. Gregory Bociek
Dolores Caballero Barrigón
Eva González-Barca
Mehmet Turgut
John F. Gerecitano
Fabian Herbst
L S Williams
Nabanita Mukherjee
Ranjana Tavorath
Won-Seog Kim
Show All
Source
Cite
Save
Citations (16)
1